TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04135885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
Study: NCT02730871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brinzolamide/brimonidine vehicle
Description: Inactive ingredients used as placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% solution
Description: 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Travoprost 0.004%/timolol 0.5% solution
Description: 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
Study: NCT02703558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenazopyridine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein
Study: NCT03197116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone reminder
Description: Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No other
Description: No additional reminder will be offered
Study: NCT04570592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg
Description: Comparing PONV incidences in both arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron 1 Mg/mL Intravenous Solution
Description: Comparing PONV incidences in both arms
Study: NCT00823472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mild stimulation
Description: Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mild stimulation
Description: Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
Study: NCT01646749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content (En%) of meals
Description: The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content (En%) of meals
Description: The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content (En%) of meals
Description: The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
Study: NCT00766649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
Study: NCT00996749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Given PO
Study: NCT02131246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
Study: NCT00996749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone scan
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual x-ray absorptometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study: NCT00391196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo plus non-pharmacological weight loss program.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Subjects receive CP-945,598 plus non-pharmacological weight loss program.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment B
Description: Subjects receive CP-945,598 plus non-pharmacological weight loss program.
Study: NCT02918656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infographic presentation of health information
Description: The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PLS presentation of health information
Description: The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scientific abstract presentation of health information
Description: The students in scientific abstract group will read the the text written for the academic population and practitioners.
Study: NCT04019444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd155-RG
Description: The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd155-RG
Description: The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd155-RG
Description: The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride, USP injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride, USP injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride, USP injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride, USP injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
Study: NCT02840526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (PVB)
Description: preoperative ThPVB performed unilaterally at Th10 level

Intervention type: DRUG
Group type: OTHER
Intervention: Sopodorm
Description: midazolam 0,1 mgkg-1 intravenously (anesthesia induction)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sopodorm
Description: midazolam 0,1 mgkg-1 intravenously (anesthesia induction)

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol WZF
Description: propofol 2 mgkg-1intravenously (anesthesia induction)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol WZF
Description: propofol 2 mgkg-1intravenously (anesthesia induction)

Intervention type: DRUG
Group type: OTHER
Intervention: Nimbex
Description: cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimbex
Description: cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)

Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl WZF
Description: fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl WZF
Description: fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)

Intervention type: DRUG
Group type: OTHER
Intervention: Sevorane
Description: sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevorane
Description: sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance

Intervention type: DEVICE
Group type: OTHER
Intervention: Intubation
Description: Intratracheal intubation with a single lumen endotracheal tube
Study: NCT03633656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model Predictive Control of Iron Dosing
Description: Model Predictive Control of Iron Dosing
Study: NCT01876420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CoreValve™ Evolut R TAV™ system
Description: CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 \& 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
Study: NCT00687466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour.
Study: NCT02840526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intratracheal intubation with a single lumen endotracheal tube

Intervention type: DRUG
Group type: OTHER
Intervention: Oxynorm
Description: 1 mgml-1 concentration oxycodone solution intravenously
Study: NCT01941875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Effervescent Vaginal Tablets
Description: Experimental
Study: NCT02840526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxynorm
Description: 1 mgml-1 concentration oxycodone solution intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol Kabi
Description: 1g paracetamol intravenously every 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol Kabi
Description: 1g paracetamol intravenously every 6 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Ketonal
Description: 100 mg ketoprofen intravenously every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketonal
Description: 100 mg ketoprofen intravenously every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine WZF
Description: 0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
Study: NCT02707939

Intervention type: OTHER
Intervention: Observation
Description: Patients will be observed before and after they receive anesthesia
Study: NCT02996955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social support
Description: behaviour change intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment of illness perceptions
Description: educational interview
Study: NCT02996955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment of illness perceptions
Description: educational interview
Study: NCT02099708

Intervention type: DRUG
Intervention: Lansoprazole
Description: Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
Study: NCT02996955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activ8
Description: wearing a move monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activ8
Description: wearing a move monitor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: activity advice
Description: walking or cycling 5 days a week during at least half an hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity advice
Description: walking or cycling 5 days a week during at least half an hour
Study: NCT03514888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: 40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
Study: NCT02322099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate and colecalciferol
Description: Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate and colecalciferol
Description: Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir disoproxil
Description: Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
Study: NCT03249948

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vector change defibrillation
Description: Defibrillation using pad placement in anterior-posterior position.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Double-sequential defibrillation
Description: Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
Study: NCT00002941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT00621088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intertan
Description: Operations performed either with a Sliding Hip Screw or a nail (Intertan)
Study: NCT02867163

Intervention type: DRUG
Intervention: Tranexamic Acid
Description: Intravenous or local administration of TXA, in any dosage
Study: NCT01250652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: 20 mg levocetirizine for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine plus Hydroxyzine
Description: 24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
Study: NCT02251158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tipranavir capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir soft gel capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat breakfast
Study: NCT01316029

Intervention type: PROCEDURE
Intervention: Okada Purifying Therapy
Description: Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
Study: NCT01661946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
Study: NCT00987090

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic and neuropsychologic evaluation
Description: evaluation at the inclusion and 18 months after

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinic and neuropsychologic evaluation
Description: evaluation at the inclusion and 18 months after

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: intervention at the inclusion and 18 months after
Study: NCT00690794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
Study: NCT01187654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AC133
Description: intra coronary injection of bone marrow derived AC133+ cells